Welcome to our dedicated page for Rockwell Med news (Ticker: RMTI), a resource for investors and traders seeking the latest updates and insights on Rockwell Med stock.
Rockwell Medical develops, manufactures, commercializes, and distributes hemodialysis products for dialysis providers worldwide. Company news centers on financial and operational results, gross margin and cash flow trends, supply-chain and distribution initiatives, and customer activity tied to dialysis clinics and large dialysis-service providers.
Recurring updates also cover product purchase agreements, expanded delivery capabilities in U.S. regions, additions to the customer clinic footprint, operational changes aimed at improving gross profit, and corporate communications such as earnings release schedules and workplace-related announcements.
Rockwell Medical (Nasdaq: RMTI) announced it has regained compliance with Nasdaq’s minimum bid price requirement under Listing Rule 5550(a)(2). The company’s shares maintained a closing bid price of at least $1.00 from July 1, 2026 to July 15, 2026, leading Nasdaq to close the compliance matter. Rockwell Medical is now in full compliance with all Nasdaq continued listing requirements, and its stock continues to trade on the Nasdaq Capital Market under the ticker RMTI.
Rockwell Medical (Nasdaq: RMTI) announced it will release its financial and operational results for the second quarter ended June 30, 2026, on Thursday, August 13, 2026. A press release will be issued at 6:00 a.m. ET, followed by a live webcast at 8:00 a.m. ET via www.RockwellMed.com/Results, featuring President and CEO Mark Strobeck and CFO Jesse Neri, with a Q&A session.
Rockwell Medical (Nasdaq:RMTI) will implement a 1-for-10 reverse stock split of its issued and outstanding common shares, effective 12:01 a.m. EDT on July 1, 2026. The action aims to help regain compliance with Nasdaq’s $1.00 minimum bid requirement while preserving existing rights and par value.
The ticker remains RMTI, with new CUSIP 774374409. No fractional shares will be issued; eligible holders receive cash in lieu based on the June 30, 2026 adjusted closing price.
Rockwell Medical (Nasdaq:RMTI) renewed and extended its product purchase agreement with aQua Dialysis, a leading independent dialysis provider in Texas. The contract runs for two years with options for two additional one-year renewals.
Rockwell will continue supplying liquid and dry acid and bicarbonate hemodialysis concentrates and other essential dialysis products to aQua Dialysis clinics.
Rockwell Medical (Nasdaq:RMTI) signed a new three-year product purchase agreement with Heritage Dialysis, a Michigan-based provider focused on home dialysis in skilled nursing, assisted living, senior living communities, and patients' homes.
The agreement includes mutual supply and purchasing commitments, options for three additional one-year renewals, and covers Rockwell Medical’s hemodialysis portfolio, including PureCart 720g bicarbonate cartridges, RenalPure liquid acetic-acid concentrate, SteriLyte liquid bicarbonate, and other ancillary dialysis products.
Rockwell Medical (NASDAQ: RMTI) reported Q1 2026 net sales of $17.3M, gross profit of $2.9M and a 17% gross margin. Net loss was $1.6M and Adjusted EBITDA was ($0.3M). Cash and investments totaled $23.9M at March 31, 2026.
The company expects operational changes and pricing to generate >$3M of annualized gross profit improvement and updated 2026 guidance: $70–75M net sales, 18–22% gross margin, $1–2M Adjusted EBITDA, and positive operating cash flow.
Rockwell Medical (Nasdaq: RMTI) will release its first quarter 2026 financial and operational results on Thursday, May 7, 2026. The company will issue a press release at 6:00am ET followed by a live webcast at 8:00am ET with replay available.
Speakers include Mark Strobeck, Ph.D., president and CEO, and Jesse Neri, SVP and CFO. The webcast and replay will be available at www.RockwellMed.com/Results and will include discussion of results followed by a Q&A session.
Rockwell Medical (Nasdaq: RMTI) reported fourth-quarter 2025 net sales of $18.3M and full-year net sales of $69.3M. The company was profitable on an Adjusted EBITDA basis for both Q4 and full-year 2025, achieved a Q4 gross margin of 21%, and ended 2025 with $25.0M in cash and investments.
The company extended a major purchase agreement through Dec 31, 2026 with increased pricing, added 30 new western U.S. customers, and issued 2026 guidance targeting $1M–$2M Adjusted EBITDA and positive operating cash flow.
Rockwell Medical (Nasdaq: RMTI) will release fourth-quarter and full-year 2025 results on Thursday, March 26, 2026. A press release will be issued at 6:00 AM ET followed by a live webcast at 8:00 AM ET.
Management speakers include Mark Strobeck, Ph.D., president and CEO, and Jesse Neri, SVP and CFO. The webcast will include discussion of financial and operational results followed by a Q&A. Replay will be available at www.RockwellMed.com/Results.
Rockwell Medical (NASDAQ: RMTI) announced it was certified as a Great Place to Work for the fourth consecutive year on February 12, 2026. The company highlighted employee dedication and said the recognition supports its culture focused on quality, reliability and service for dialysis providers and patients.